新型抗反流消融治疗胃食管反流病的临床可行性(含视频)
本研究评估了新型抗反流消融治疗(ARAT)对无滑动性食管裂孔疝的质子泵抑制剂(PPI)难治性胃食管反流病(GERD)患者的可行性。108例患者接受ARAT,36个月时84例完成随访,酸暴露时间(AET)、DeMeester评分和GERD-HRQL评分显著下降并维持,无严重不良事件,12.9%出现狭窄但球囊扩张有效。结论认为ARAT安全有效,但需更长期随访和随机对照研究。
要点
- ARAT可显著改善无食管裂孔疝的PPI难治性GERD患者的反流指标和生活质量。
- 36个月成功(AET<4%)率为72.2%,3个月为89%。
- 术后狭窄发生率12.9%,球囊扩张(<5次)可缓解。
核心结论
- ARAT对无滑动性食管裂孔疝的GERD患者早期和中期治疗可行、安全且有效。
- 需更长期随访和随机对照研究明确其真正作用。
研究设计与样本
- 前瞻性单臂研究,纳入2016年1月至2019年10月间无食管裂孔疝的PPI难治性GERD患者108例。
- 在ARAT后3、6、12、24和36个月记录GERD-HRQL、上消化道内镜、24小时pH监测和PPI使用情况。
主要发现
- 108例患者中男性61例(56.5%),中位年龄36.5岁(范围18-78岁)。
- ARAT中位时间35.5分钟(范围22-51分钟),中位消融周径300°(范围270°-320°)。
- 无重大不良事件,14/108例(12.9%)出现狭窄,对球囊扩张(<5次)有效。
- 3个月时AET从18.8%降至2.8%(P=.001),DeMeester评分从42.5降至9.1(P=.001),GERD-HRQL评分从36.5降至10(P=.02),并维持至36个月。
- 成功(AET<4%)在3个月和36个月分别为89%和72.2%;36个月相关因素包括术前Hill II型(OR 3.212,95%CI 1.431-5.951,P=.033)、术后3个月Hill I型(OR 4.101,95%CI 1.812-9.121,P=.042)和3个月AET<4%(OR 5.512,95%CI 1.451-7.621,P=.021)。
临床怎么用
- 对于无滑动性食管裂孔疝的PPI难治性GERD患者,ARAT可作为可选治疗方式。
- 术后需关注狭窄发生,球囊扩张可有效处理。
- 术前Hill分型和术后3个月AET可能有助于预测长期疗效。
局限性
- 单臂研究,无对照组。
- 随访36个月时仅84例完成方案。
- 需更长期随访和随机对照研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUNDS AND AIMS: New mucosal resective and ablative endoscopic procedures based on gastric cardiac remodeling to prevent reflux have appeared. We aimed to evaluate the feasibility of a new ablative technique named antireflux ablation therapy (ARAT) for control of GERD in patients without hiatal hernia. METHODS: Patients with proton pump inhibitor (PPI)-refractory GERD without hiatal hernia underwent ARAT between January 2016 and October 2019. Gastroesophageal Reflux Disease-Health-Related Quality of Life (GERD-HRQL), upper endoscopy, 24-hour pH monitoring, and PPI use were documented at 3, 6, 12, 24, and 36 months after ARAT. RESULTS: One hundred eight patients were included (61 men [56.5%]; median age, 36.5 years; range, 18-78 years). ARAT was performed on all patients. At the 36-month evaluation, 84 patients had completed the protocol. Median ARAT time was 35.5 minutes (range, 22-51 minutes), and median circumference ablation was 300° (range, 270°-320°). No major adverse events occurred, and 14 of 108 patients (12.9%) presented with stenosis that was responsive to balloon dilation (<5 sessions). At the 3-month evaluation, the acid exposure time (AET), DeMeester score, and GERD-HRQL score had decreased from 18.8% to 2.8% (P = .001), 42.5 to 9.1 (P = .001), and 36.5 to 10 (P = .02), respectively, and these values were maintained up to 36 months. Success (AET <4%) was achieved in 89% and 72.2% at 3 and 36 months, respectively. Related factors at 36 months were as follows: pre-ARAT Hill type II (odds ratio [OR], 3.212; 95% confidence interval [CI], 1.431-5.951; P = .033), post-ARAT 3-month Hill type I (OR, 4.101; 95% CI, 1.812-9.121; P = .042), and AET <4% at 3 months (OR, 5.512; 95% CI, 1.451-7.621; P = .021). CONCLUSIONS: ARAT is a feasible, safe, and effective therapy for early and mid-term treatment of GERD in patients without a sliding hiatal hernia. However, longer follow-up evaluations and randomized comparative studies are needed to clarify its real role. (Clinical trial registration number: NCT03548298.).
引用
- Hernández Mondragón OV, Zamarripa Mottú RA, García Contreras LF, et al. Clinical feasibility of a new antireflux ablation therapy on gastroesophageal reflux disease (with video). Gastrointest Endosc. 2020. PMID: 32343977. doi:10.1016/j.gie.2020.04.046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。